HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

peginterferon alfa-2b (Pegintron)

Subscribe to New Research on peginterferon alfa-2b

Also Known As:

Pegintron; Essex brand of peginterferon alfa-2b; Merck brand of peginterferon alfa-2b; PEG INF alfa-2b; PEG INF alpha-2b; PEG-IFNalpha-2b; PEG-Intron; ViraferonPeg; pegylated interferon alfa-2b; polyethylene glycol-interferon alfa-2b

Networked: 222 relevant articles (33 outcomes, 53 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Albrecht, Janice K: 9 articles (05/2014 - 11/2003)
2.	Brass, Clifford A: 8 articles (05/2014 - 10/2007)
3.	Berg, Thomas: 8 articles (06/2013 - 07/2006)
4.	Albrecht, Janice: 7 articles (02/2011 - 05/2002)
5.	Prous, J R: 7 articles (09/2007 - 06/2004)
6.	Rabasseda, X: 7 articles (09/2007 - 06/2004)
7.	Manns, Michael P: 6 articles (05/2014 - 09/2003)
8.	Pedicone, Lisa D: 6 articles (05/2014 - 08/2009)
9.	Burroughs, Margaret: 6 articles (05/2014 - 05/2009)
10.	Poynard, Thierry: 6 articles (03/2013 - 05/2002)

Related Diseases

1.	Chronic Hepatitis C 04/01/2010 - "Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials." 02/01/2007 - "Satisfaction of patients treated for chronic hepatitis C with the peginterferon alfa-2b pen device: the VISA observational study." 12/01/2013 - "Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C." 12/01/2010 - "Proceed with caution: peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. " 12/01/2007 - "A systematic review of the cost-effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C."
2.	Infection 01/15/2013 - "For genotype 2 or 3 infection, dual therapy for 12 to 16 weeks was associated with a lower likelihood of SVR than was therapy for 24 weeks, and lower doses of pegylated interferon alfa-2b were less effective than standard doses (2 to 4 fair-quality trials). " 03/01/2006 - "Patients whose infection did not spontaneously resolve by week 8 were randomized to once weekly peginterferon alfa-2b monotherapy (1.5 microg/kg per week) started at weeks 8, 12, or 20 for a duration of 12 weeks. " 06/01/2005 - "Pegylated interferon alfa-2b (PEG-IFN-alfa 2b ) has been shown to provide superior efficacy to IFN-alfa 2b in patients with chronic hepatitis C (predominantly genotype 1) infection as measured by viral clearance. " 07/15/2002 - "Studies in patients with chronic hepatitis C infection and malignancies have demonstrated both biologic and clinical activity of PEG Intron and have provided empiric data to compare the pharmacokinetics (PK) and pharmacodynamics of PEG Intron and IFN-alpha-2b. " 06/01/2005 - "Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection."
3.	Hepatitis C 03/01/2006 - "This randomized trial assessed the efficacy, safety, and timing of pegylated interferon alfa-2b for treatment of acute hepatitis C. " 08/01/2006 - "Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response." 03/01/2006 - "Peginterferon alfa-2b monotherapy in acute hepatitis C induces high sustained virologic response rates, prevents chronic evolution, and is well tolerated. " 03/01/2006 - "Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response." 02/01/2005 - "Peginterferon alfa-2b treatment for patients affected by acute hepatitis C: presentation of six case reports."
4.	Chronic Hepatitis B 08/21/2013 - "Serum samples were obtained from patients with chronic hepatitis B who were receiving peginterferon alfa-2b. " 01/08/2005 - "Treatment with pegylated interferon alfa-2b is effective for HBeAg-positive chronic hepatitis B. " 01/01/2006 - "Similar efficacy of peginterferon alfa-2b has also been demonstrated in HBeAg-positive chronic hepatitis B. " 12/01/2014 - "Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: a randomized trial." 08/21/2013 - "Serum proteins in chronic hepatitis B patients treated with peginterferon alfa-2b."
5.	Neoplasms (Cancer) 09/15/2002 - "We conducted a phase I/II study to determine the maximum-tolerated dose (MTD), the safety and tolerability, and the preliminary efficacy of once-weekly pegylated interferon alfa-2b (IFNalpha-2b) in patients with advanced solid tumors (primarily RCC). " 07/15/2002 - "Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation." 09/15/2002 - "Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study." 03/01/2003 - "Pegylated interferon alfa-2b as treatment of patients with solid tumors." 07/15/2002 - "Dose intensification can be achieved safely in patients with CML and solid tumors using PEG Intron, which could improve efficacy. "

Related Drugs and Biologics

1.	Ribavirin (Virazole)
2.	Interferons
3.	peginterferon alfa-2b (Pegintron)
4.	peginterferon alfa-2a (Pegasys)
5.	Hepatitis B e Antigens
6.	Interferon Alfa-2b (Interferon Alfa 2b)
7.	Lamivudine (3TC)
8.	Antigens
9.	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamide
10.	Interferon-alpha (Interferon Alfa)

Related Therapies and Procedures

1.	Liver Transplantation
2.	Kidney Transplantation
3.	Stents
4.	Retreatment
5.	Drug Therapy (Chemotherapy)